Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
出版年份 2021 全文链接
标题
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
作者
关键词
-
出版物
Lancet Diabetes & Endocrinology
Volume 9, Issue 11, Pages 755-766
出版商
Elsevier BV
发表日期
2021-10-06
DOI
10.1016/s2213-8587(21)00243-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
- (2021) David C. Wheeler et al. KIDNEY INTERNATIONAL
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Renal effects of dapagliflozin in people with and without diabetes with moderate or severe renal dysfunction: prospective modeling of an ongoing clinical trial.
- (2020) Karen Melissa Hallow et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
- (2020) Megumi Oshima et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
- (2020) Simke W. Waijer et al. Journal of the American Heart Association
- Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
- (2020) Rio P. Juni et al. KIDNEY INTERNATIONAL
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- (2018) Paola Fioretto et al. DIABETES OBESITY & METABOLISM
- A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
- (2018) Yifan Zhang et al. KIDNEY INTERNATIONAL
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- The effect of liraglutide on renal function: A randomized clinical trial
- (2016) Bernt J. von Scholten et al. DIABETES OBESITY & METABOLISM
- Microalbuminuria: target for renoprotective therapy PRO
- (2014) Sara S. Roscioni et al. KIDNEY INTERNATIONAL
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria
- (2008) E. C. Witte et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started